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Immunomodulatory drug
IMiD
Revlimid
PomalystThalidomide and its derivatives lenalidomide and pomalidomide are important anticancer agents but can
cause severe birth defects via an interaction with the protein cereblon. The ligand-binding domain of
cereblon is found, with a high degree of conservation, in both bacteria and eukaryotes. Using a bacterial
model system, we reveal the structural determinants of cereblon substrate recognition, based on a series
of high-resolution crystal structures. For the ﬁrst time, we identify a cellular ligand that is universally
present: we show that thalidomide and its derivatives mimic and compete for the binding of uridine,
and validate these ﬁndings in vivo. The nature of the binding pocket, an aromatic cage of three tryptophan
residues, further suggests a role in the recognition of cationic ligands. Our results allow for general
evaluation of pharmaceuticals for potential cereblon-dependent teratogenicity.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Thalidomide was originally introduced for its sedative and
anti-emetic properties in the 1950s, but banned from the market
in the early 1960s due to teratogenic effects that had led to severe
developmental defects in about 10,000 newborns. In the decades
after its withdrawal, it was also discovered to possess anti-
inﬂammatory, immunomodulatory and anti-angiogenic properties,
thus promising valuable treatment for a broad range of clinical
conditions (Bartlett et al., 2004; Franks et al., 2004). Especially,
its success as an anti-cancer agent paved the road for a renaissance
and promoted the development of a new class of immunomodula-
tory drugs (IMiDs) based on thalidomide as a lead compound.
However, many important and promising derivatives like lenalido-
mide (CC-5013, Revlimid) and pomalidomide (CC-4047, Pomalyst)
potentially inherited thalidomide’s teratogenic properties, severely
limiting their use.
Thalidomide consists of a phthaloyl ring and a glutarimide ring
with a chiral carbon; it racemizes in vivo and only the (S)-enantio-
mer is thought to be teratogenic (Bartlett et al., 2004; Franks et al.,
2004). Lenalidomide and pomalidomide have the same architec-
ture with modiﬁed phthaloyl moieties (Fig. 1). In 2010, Handa
and co-workers identiﬁed the protein cereblon as a primary targetof thalidomide (Ito et al., 2010). They showed that cereblon associ-
ates with damaged DNA binding protein 1 (DDB1), a core compo-
nent of the DDB1/cullin4 (CUL4) E3 ubiquitin ligase complex
which is known as a key player in the nucleotide excision repair
pathway. These E3 ligase complexes employ a large number of
different DDB1-CUL4-associated factors (DCAFs) with different
substrate speciﬁcity as substrate receptors (Iovine et al., 2011).
Cereblon constitutes a novel DCAF for this complex, altering its
ubiquitin ligase activity upon thalidomide binding, which may in
turn cause its teratogenic effects. The region critical for DDB1
binding was found to reside in the middle part of the cereblon
protein, whereas the binding site for thalidomide was mapped to
the C-terminal 104 amino acids: the two point mutants of human
cereblon hCrbnY384A and hCrbnW386A and especially the double
mutant hCrbnYW/AA had signiﬁcantly lowered thalidomide-binding
activity. Also lenalidomide and pomalidomide were shown to bind
to cereblon, competing for the same binding site (Lopez-Girona
et al., 2012). Moreover, it was found that the degradation of the
transcription factors Ikaros and Aiolos by the Cereblon/DDB1/
CUL4 E3 ligase is stimulated by these IMiDs in multiple myeloma
cells (Gandhi et al., 2014; Kronke et al., 2014). These downstream
factors can however only represent a subset of the natural targets,
as they do not occur outside the animal kingdom, whereas
cereblon occurs throughout eukaryotes, except fungi.
By sequence analysis (Lupas et al., 2014), human cereblon is a
multi-domain protein: an N-terminal intrinsically unstructured
region is followed by a LON domain and a C-terminal domain that
contains the thalidomide-binding site deﬁned by Ito et al. (2010).
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of unknown activity, binding cellular ligands and thalidomide), is
also found as the sole domain in two other protein families, one
comprising secreted proteins of eukaryotes and the other cytosolic
proteins of bacteria. CULT domains contain three strictly conserved
tryptophan residues, one of which (W386 in hCrbn) was identiﬁed
as critical for thalidomide binding (Ito et al., 2010).
Searches for distant homologs show that the CULT domain is
related to proteins sharing a common fold formed by two four-
stranded, antiparallel b-sheets that are oriented at approximately
a right angle, and pinned together at their tip by a zinc ion
(Lupas et al., 2014). We have named this fold the b-tent for the
prominent arrangement of its b-sheets. Proteins of this fold show
considerable functional and structural divergence, including an
absence of most sequence motifs characteristic for CULT domains;
however, the location of the substrate binding site appears to be
conserved among all members of the fold (Lupas et al., 2014).
Here we determined crystal structures of a bacterial CULT
domain from Magnetospirillum gryphiswaldense MSR-1, bound to
thalidomide and other ligands. With a sequence identity of 35%,
it is as similar to the human thalidomide binding domain as
domains from other eukaryotic clades. Substantiated by an NMR-
based assay and in vivo data, the structures provide the molecular
basis for thalidomide teratogenicity and, for the ﬁrst time, reveal
potential natural ligands that are universally present in all
organisms with cereblon proteins.2. Experimental procedures
2.1. Cloning
The gene encoding MsCI4 was synthesized codon-optimized for
expression in Escherichia coli. It was cloned in pETHis_1a, a modi-
ﬁed pETM vector (sequence available at http://www.embl.de/
pepcore/pepcore_services/strains_vectors/vectors/bacterial_expres-
sion_vectors/index.html) for overexpression of the protein in E. coli
with a N-terminal hexa-histidine tag followed by a cleavage site of
TEV (Tobacco Etch Virus) protease.
Mutants MsCI4YW/AA and MsCI4Y101F were constructed using
QuikChange Site-Directed Mutagenesis Kit (Stratagene) with wild
type MsCI4 in pETHis_1a as a template and mutagenic primers. The
correctness of all clones was veriﬁed by DNA sequencing.2.2. Protein expression and puriﬁcation
All proteins were expressed in E. coli C41 (DE3) cells. After
induction of protein expression in the logarithmic phase at
A600 = 0.6, the cultures were shaken for 4 h at 37 C. Cells were
pelleted, resuspended in 20 mM Tris, pH 7.5, 100 mM NaCl,
5 mM 2-Mercaptoethanol, 4 mM MgCl2 , DNase I and Protease
Inhibitor Cocktail (Roche Applied Science), and lysed using a
French pressure cell. After centrifugation of the extract, the super-
natant was applied on a NiNTA agarose column equilibrated in
20 mM Tris, pH 7.9, 300 mM NaCl, 5 mM 2-Mercaptoethanol. His-
tidine tagged proteins were eluted with a gradient of 0–0.5 M
imidazole. MsCI4 wildtype or mutant protein containing fractions
were pooled and dialyzed against 20 mM Tris, pH 7.5, 150 mM
NaCl, 5 mM 2-Mercaptoethanol. The histidine tag was cleaved
overnight at 4 C by TEV protease. The protein mixture was loaded
on a NiNTA column to which the histidine tagged TEV protease and
the cleaved linker bound. Cleaved MsCI4 proteins were found to
be in the ﬂow through. They were pooled and concen-
trated to 14 mg/ml in 20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM
2-Mercaptoethanol.2.3. NMR spectroscopy
Comparison of spectra of MsCI4 alone and in presence of thalid-
omide revealed signiﬁcant chemical shift changes for many reso-
nances, including several prominent, upﬁeld-shifted methyl
groups. One such methyl group shifts from 0.31 to 0.89 ppm
on binding of thalidomide, providing a trivial assay for ligands
employing a thalidomide-like binding mode. Typically, 1D proton
spectra were acquired on 50 lM protein samples both alone and
in the presence of 10–500 lM ligand. Uracil, uridine and deoxyur-
idine induce these characteristic chemical shift changes at the low-
est concentrations tested. Other pyrimidine nucleobases and
nucleosides tested (cytosine, cytidine, deoxycytidine, thymidine
and deoxythymidine) did not, with concentrations of at least
500 lM. For these compounds ligand-detected experiments (STD
(Meyer and Peters, 2003) and water-LOGSY (Dalvit et al., 2000))
were also used to probe for binding where characteristic chemical
shift changes were not detected. Here ligand protein concentration
ratios of 10:1 were employed with ligand concentrations of
500 lM. A negative result in these experiments used to place a
conservative lower limit on binding afﬁnity at twice this concen-
tration, i.e. 1 mM. These assays were repeated for the MsCI4Y101F
mutant (thalidomide, uracil, uridine and deoxyuridine) and for the
MsCI4YW/AA double mutant (thalidomide and uridine).2.4. Crystallography
Crystallization trials were performed at 294 K in 96-well
sitting drop plates with 50 ll of reservoir solution and drops
containing 400 nl of protein solution in addition to 400 nl of
reservoir solution. The protein solution in the individual
co-crystallization trials contained the additives listed in Table 1,
in addition to 17 mg/ml of protein in 20 mM Tris, pH 7.5,
150 mM NaCl, 5 mM 2-Mercaptoethanol. Most of the different
co-crystallization trials yielded crystals in multiple similar
conditions. The conditions for the crystals used for structure
determination are listed in Table 1. All crystals were loop
mounted and ﬂash-cooled in liquid nitrogen. Where necessary,
crystals were transferred into a separate drop of cryo-solution
as indicated in Table 1 prior to ﬂash-cooling. All data were
collected at beamline X10SA (PXII) at the SLS (Paul Scherrer
Institute, Villigen, Switzerland) at 100 K using a PILATUS 6 M
detector (DECTRIS) at a wavelength of 1 Å. Diffraction images
were processed and scaled using the XDS program suite
(Kabsch, 1993). The ﬁrst structure, MsCI4thalidomide, was
solved exploiting the anomalous signal of the structural zinc
ions. Three zinc sites, belonging to the three monomers in the
asymmetric unit, were identiﬁed with SHELXD (Sheldrick,
2008). Density modiﬁcation with SHELXE yielded an electron
density map of excellent quality, which was subsequently traced
with ARP/WARP (Perrakis et al., 1999). The structures of
MsCI4pomalidomide, MsCI4lenalidomide, MsCI4deoxyuridine
and MsCI4Y101Fthalidomide were subsequently solved based on
the MsCI4thalidomide coordinates. All structures were com-
pleted by cyclic manual modeling with Coot (Emsley and
Cowtan, 2004) and reﬁnement with REFMAC5 (Murshudov
et al., 1999). Analysis with Procheck (Laskowski et al., 1993)
showed excellent geometries for all structures. Data collection
and reﬁnement statistics are summarized in Table 2. All molec-
ular depictions were prepared using MolScript (Kraulis, 1991)
and Raster3D (Merritt and Bacon, 1997). All coordinates and
structure factors were deposited in the Protein Data Bank
(PDB) under the accession codes 4V2Y (MsCI4thalidomide),
4V2Z (MsCI4pomalidomide), 4V30 (MsCI4lenalidomide), 4V31
(MsCI4deoxyuridine) and 4V32 (MsCI4Y101Fthalidomide).
Fig.1. How cereblon recognizes its ligands. (a) The structure of thalidomide, its derivatives, and related pyrimidine nucleosides. Encircled in green are the functional groups
that are recognized by cereblon; encircled and crossed out in red are groups that are incompatible with the binding pocket. Pomalidomide and lenalidomide have modiﬁed
phthaloyl rings but the same glutarimide ring as thalidomide and are therefore bound in the same way. The uracil moiety of uridine is bound in the same way as the
glutarimide ring of thalidomide, whereas the thymine moiety of thymidine is too bulky and the cytosine moiety of cytidine cannot form the necessary hydrogen bonds. (b)
Cartoon representation of one monomer of MsCI4 in complex with thalidomide in two orientations. Shown in detail are the three tryptophan residues forming the boundaries
of the binding pocket, Y101 (white), and four conserved cysteines that coordinate a structural zinc ion. In the left orientation, an approximate twofold symmetry axis is
apparent, which relates the beta sheet in dark gray color to the beta sheet in light gray color; this axis passes through the zinc binding site. (c) Sequence alignment of MsCI4
with the thalidomide-binding domain of human Cereblon, together with the secondary structure of the crystal structure. The residues in the binding site are highlighted in
bold red, the cysteines of the zinc binding site in red. Identical residues are marked with ‘‘|’’, similar residues with ‘‘:’’. The sequence identity is 35% over 104 aligned positions.
(d) Detailed view of the binding pocket of MsCI4 in complex with different ligands, including a superposition of the pocket in complex with thalidomide and deoxyuridine,
and a detailed view of the MsCI4Y101F mutant pocket in complex with thalidomide. Highlighted are the hydrogen bonds formed between the ligands and the protein.
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A zebraﬁsh pectoral ﬁn deformity assay was performed as
described by Ito et al. (2010) with the following modiﬁcations:
(1) The zebraﬁsh cereblon (zcrbn) gene, as annotated at http://
www.ensembl.org, was ampliﬁed by PCR from cDNA; (2) The exam-
ined species was Danio rerio leot1; (3) zcrbn mRNA was dissolved innuclease-free water at 200 ng/ll; (4) The length of the pectoral ﬁns
was measured using self-developed software, which allows curva-
ture determination in a semi-automatic fashion. The deformity
was classiﬁed as ‘‘no effect’’ for ﬁns exceeding 85% of the control
length, ‘‘mild’’ for ﬁns corresponding to 75–85% of the control
length, ‘‘medium’’ for ﬁns shortened to 60–75%, and ‘‘severe’’ for
ﬁns shorter than 60% of the control length.
Table 1
Crystallization conditions and cryo protection.
Structure Protein solution additives Reservoir solution (RS) Cryo solution
MsCI4thalidomide 3 mM thalidomide
3% (v/v) DMSO
0.1 M magnesium chloride
0.1 M sodium citrate pH 5
15%(w/v) PEG 4000
RS + 15% (v/v) PEG 300
MsCI4pomalidomide 3 mM pomalidomide
3% (v/v) DMSO
0.1 M sodium acetate pH 4.6
15 %(w/v) PEG 20,000
RS + 15% (v/v) PEG 300
MsCI4lenalidomide 3 mM lenalidomide
3% (v/v) DMSO
15 %(w/v) PEG 6000
5 %(w/v) glycerol
RS + 10% (v/v) PEG 300
MsCI4deoxyuridine 3 mM deoxyuridine 0.1 M citric acid pH 3.5
25 %(w/v) PEG 3350
–
MsCI4Y101Fthalidomide 3 mM thalidomide
3% (v/v) DMSO
0.2 M sodium chloride
0.1 M phosphate-citrate pH 4.2
20 %(w/v) PEG 8000
RS + 10% (v/v) PEG 300
Table 2
Data collection and reﬁnement statistics.
MsCI4thalidomide MsCI4pomalidomide MsCI4lenalidomide MsCI4deoxyuridine MsCI4Y101Fthalidomide
Data collection
Space group P212121 P212121 P212121 P212121 P212121
Cell dimensions a, b, c (Å) 56.5, 60.1, 88.5 56.5, 60.1 88.5 56.7, 59.7, 88.1 56.8, 60.0, 88.4 56.8, 60.0, 88.4
Resolution (Å) 37.3–1.40 (1.48–1.40)a 37.3–1.45 (1.54–1.45)a 37.3–1.85 (1.96–1.85)a 37.4–1.80 (1.91–1.80)a 37.4–1.90 (2.01–1.90)a
Rmerge 7.4 (73.2) 3.8 (44.9) 7.3 (41.6) 8.5 (50.5) 8.6 (77.3)
I/rI 12.46 (1.73) 16.32 (2.45) 8.41 (1.96) 8.71 (2.33) 15.06 (2.59)
Completeness (%) 99.6 (97.7) 99.5 (99.1) 98.7 (98.0) 98.8 (97.4) 99.9 (99.5)
Redundancy 6.69 (6.39) 3.40 (3.37) 2.86 (2.81) 2.87 (2.74) 6.99 (6.91)
Reﬁnement
Resolution (Å) 37.3–1.40 37.3–1.45 37.3–1.85 37.4–1.80 37.4–1.90
No. reﬂections 57,028 51,290 24,829 27,173 23,212
Rwork/Rfree 0.16/0.19 0.17/0.20 0.19/0.24 0.16/0.22 0.18/0.24
PDB code 4V2Y 4V2Z 4V30 4V31 4V32
a Highest resolution shell is shown in parenthesis.
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3.1. Cereblon isoform 4 from M. gryphiswaldense
For crystallization and in vitro experiments, we designed con-
structs of full-length cereblon and isolated thalidomide binding
domains from different eukaryotes as well as one bacterial repre-
sentative, cereblon isoform 4 from M. gryphiswaldense MSR-1
(MsCI4; 124 residues). While the work with the eukaryotic con-
structs was cumbersome and did not yield crystals, the bacterial
protein was highly rewarding: With soluble expression in E. coli
at high yields and facile puriﬁcation with standard chromatogra-
phy methods, it poses a very robust model system. Further, we
expressed and puriﬁed two mutants of MsCI4. The double mutant
MsCI4YW/AA with the mutations Y83A and W85A is the equivalent
to the binding deﬁcient double mutant hCrbnYW/AA with mutations
Y384A and W386A. The other mutant is MsCI4Y101F, with a substi-
tution in the binding pocket as described later on. To conﬁrm that
MsCI4 indeed binds to thalidomide, we employed a simple NMR-
based assay that relies on chemical shift changes that occur upon
ligand binding. Thereby we found that wild-type MsCI4 and
MsCI4Y101F both have binding constants for thalidomide in the
low micromolar range, whereas the binding constant of the double
mutant MsCI4YW/AA was shifted to the millimolar range. Crystalli-
zation trials were performed for MsCI4 and MsCI4YW/AA, both in
apo form and in presence of thalidomide. Only the trial with MsCI4
and thalidomide was successful; crystals appeared within 2 days in
a wide range of conditions.
3.2. Crystal structures in complex with thalidomide, lenalidomide and
pomalidomide
The best dataset collected from these crystals could be scaled to
a resolution of 1.4 Å in space group P212121. The structure could besolved by exploiting the anomalous signal of the structural zinc
ions of the b-tent fold; three such ions were located in the asym-
metric unit, belonging to 3 MsCI4 molecules. All three monomers
are bound to thalidomide and have the same overall conformation,
resembling the expected b-tent fold with two orthogonal b-sheets
(Fig. 1).
The thalidomide binding site is formed by the three conserved
tryptophan residues W79, W85 and W99, corresponding to
W380, W386 and W400 of hCrbn, which constitute 3 sides of a
rectangular aromatic cage. W79 and W85 form opposite walls of
the cage, sandwiching the glutarimide ring at van der Waals
distance, and are orthogonal to W99. Opposite of W99, the glutari-
mide ring forms two hydrogen bonds to backbone atoms, one
between the amino group and F77O and the other between the dis-
tal keto group and W79N. A third hydrogen bond is formed
between the distal keto group and the hydroxyl group of a tyrosine,
Y101, corresponding to F402 of hCrbn, which forms the bottom of
the cage. (Fig. 1). From the racemic mixture of thalidomide used in
the crystallization trial, the (S)-enantiomer is speciﬁcally selected
by the geometry of the pocket. In further co-crystallization exper-
iments we obtained the structures of the MsCI4lenalidomide
and the MsCI4pomalidomide complex in the same crystal form
as MsCI4thalidomide. As lenalidomide and pomalidomide are
derivatives of thalidomide that are only modiﬁed in the phthaloyl
moiety, and the interactions with the binding pocket are exclu-
sively mediated via the glutarimide ring, the binding modes of
the three compounds are identical (Fig. 1).
Of all interactions that the ligands form with the binding
pocket, the hydrogen bond with Y101 is speciﬁc for MsCI4, as
Y101 corresponds to a phenylalanine (F402) in hCrbn. This led us
to conﬁrm the validity of our results in the point mutant
MsCI4Y101F, replacing the tyrosine to phenylalanine and thereby
creating a binding pocket that should be chemically indistinguish-
able from hCrbn. NMR-based measurements of this mutant with
M.D. Hartmann et al. / Journal of Structural Biology 188 (2014) 225–232 229thalidomide yielded a binding constant in the same range as for
wild-type MsCI4. This is further underpinned by a crystal structure
obtained for the MsCI4Y101Fthalidomide complex, which is identi-
cal to the wild-type complex, except for lacking a hydrogen bond
to the substituted tyrosine (Fig. 1).3.3. Uridine as a cellular ligand
Given the binding mode of thalidomide, what can we infer
about a potential natural ligand? As cereblon is supposed to act
as a DCAF of DDB1, a DNA related ligand seemed plausible. In this
context, the binding mode and the structural similarity of the glu-
tarimide ring to pyrimidine bases suggested to us that the natural
substrate of the thalidomide-binding domain might be a pyrimi-
dine nucleoside – uridine, cytidine or thymidine (Fig. 1a). Of these,
only uridine and thymidine are theoretically able to form the same
hydrogen bonds within the binding pocket as glutarimide does.
Furthermore, the cage formed by the three tryptophan residues
might sterically discriminate between thymidine and uridine, as
the additional methyl group of thymidine would clash with the
W99 side chain. We therefore assumed that the binding site would
selectively bind uridine. To test this hypothesis, we assayed MsCI4
and MsCI4Y101F with different nucleobases, nucleosides and deoxy-
nucleosides using NMR. Both proteins indeed bind uracil, uridine
and deoxyuridine with binding constants in the low micromolar
range, comparable to the results obtained for thalidomide. In con-
trast, a lower limit for the binding constants for a panel of other
pyrimidine nucleobases, nucleosides and deoxynucleosides could
be established in the millimolar range (Fig. 2). In support of
these ﬁndings, we subsequently obtained the structure of the
MsCI4deoxyuridine complex by co-crystallization, again with
the same crystal form as for MsCI4thalidomide. As anticipated,
the uracil ring of the nucleoside is bound in the same way as the
glutarimide ring of the IMiD compounds (Fig. 1).
To verify these ﬁndings in vivo, we examined the effects of
thalidomide and pyrimidine nucleosides on zebraﬁsh development
based on a pectoral ﬁn deformity assay reported by Ito et al.Fig.2. Thalidomide and nucleosides in the NMR-based ligand binding assay. The
traces show 1D proton spectra on 50 lMMsCI4 at 600 MHz. A detail is shown of the
region containing methyl groups that are up-ﬁeld shifted by close contacts with
aromatic groups, and are thus presumably within the protein core. Spectra are
shown in the absence of ligand (black) or with various ligands at the indicated
concentrations, with changes in signal positions and intensities indicative of
binding. For thalidomide (orange) and uridine (blue), a signal appears upon binding
(black arrow) that is characteristic of their speciﬁc binding mode. This signal does
not appear for cytidine (green) and thymidine (purple). Similar spectra with varying
concentrations of ligands were used to estimate binding constants. (For interpre-
tation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)(2010). Therein we found that embryos treated with uridine exhi-
bit an identical incidence of malformations as embryos treated
with thalidomide, whereas treatment with cytidine or thymidine
did not show any effect. As for thalidomide, the effect of uridine
treatment could be rescued by the injection of zcrbnYW/AA mRNA,
encoding the binding-deﬁcient double mutant of zebraﬁsh cereb-
lon (Fig. 3).3.4. The aromatic cage
While the inferences on uridine were driven by structural sim-
ilarity on the ligand side, consideration of the nature of the binding
pocket suggests yet another class of natural ligands: Aromatic
cages of similar architecture are a characteristic, if not deﬁning fea-
ture of many binding sites for compounds with methylated ammo-
nium or guanidinium groups. Therein, ligand binding is dominated
by cation-p interactions between the cationic ligand and the many
p systems of the aromatic cage (Dougherty, 1996). Examples are
found in binding sites for betaine- and choline-derived ligands in
metabolism and neurotransmission, and in binding sites for the
readout of posttranslational modiﬁcations of lysine and arginine
residues. The latter are especially prominent in histone tails, where
different methylation states of speciﬁc lysine and arginine residues
have a direct effect on chromatin structure and gene expression,
and are passed on to daughter cells as epigenetic markers
(Gayatri and Bedford, 2014; Yun et al., 2011). In Fig. 4 we compare
the aromatic cage of cereblon to representative exemplars of cages
with speciﬁcity for deﬁned methylation states of lysine and argi-
nine residues, especially of PHD-, Tudor- and Tudor-like domains
(Li et al., 2006; Su et al., 2014). While the majority of these cages
are built from a mixture of phenylalanine, tyrosine and tryptophan
residues, in individual cases they are dominated by tryptophan
residues as in cereblon. Such an example is the cage mounted on
an ankyrin repeat structure in Fig. 4. Therein, the tryptophan resi-
dues form hydrogen bonds with their indole residues that stabilize
the cage structure, which could not be formed by phenylalanine or
tyrosine. Likewise, the strictly conserved tryptophan residues in
the cereblon cage appear to serve a similar stabilizing function.
The binding of suitable ligands to the cage remains to be shown;
our ﬁrst attempts, assaying the binding of betaine- and choline
derived ligands as well as individual lysine and arginine residues
in different methylation states by NMR, were inconclusive.4. Discussion
In this study we have established a simple and robust bacterial
model system for the characterization of the CULT domain, the tha-
lidomide binding domain of cereblon. Due to its easy handling, the
bacterial protein is highly amenable to exhaustive biochemical
characterization, enabling us to screen for ligands on a large
scale. Here we report the ﬁrst results of our characterization and
screening efforts, which are driven by the insights derived from
the presented high-resolution crystal structures.
With uridine, we unravel a natural cellular ligand that is univer-
sally present. As the previously identiﬁed downstream factors
Ikaros and Aiolos are restricted to animals, they can only account
for a subset of the total range of physiological substrates of cereb-
lon. In contrast, uridine bears physiological implications for all
organisms with cereblon proteins. We have shown that of all pos-
sible nucleosides, cereblon speciﬁcally binds uridine, that uridine
causes the same teratogenic phenotype as thalidomide, and that
it competes for the same binding site. Cereblon has been impli-
cated in different activities, as in the modulation of ion channels
(Liu et al., 2014), the regulation of AMP-activated protein kinase
(Lee et al., 2011), and in the general development of the nervous
Fig.3. Zebraﬁsh pectoral ﬁn deformity resulting from thalidomide and nucleoside treatment. The images illustrate the diagnostic criteria of the pectoral ﬁns of embryos at
75 h post fertilization. Uridine treatment causes similar developmental defects as evoked by thalidomide, whereas cytidine and thymidine treated embryos remain
unaffected. As for thalidomide, the effect of uridine treatment can be rescued by injecting zcrbnYW/AA mRNA, but not by injecting zcrbn wt mRNA.
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binding is unclear. However, taken together with the fact that
cereblon is a cofactor of DDB1, a central regulator of the cellular
response to DNA damage, our results suggest that cereblon recog-
nizes uracil in DNA. Uracil occurs in DNA because of misincorpora-
tion of dUMP or deamination of cytosine, and is usually excised
by uracil-DNA glycosylases (Visnes et al., 2009). Therefore, one
possible scenario for the role of cereblon is in DNA maintenance
and quality control. However, as the DDB1-CUL4 E3 ligase system
is only present in eukaryotes, bacterial cereblon can only express
this function in another context. Indeed, MsCI4 alone showed no
afﬁnity for uracil-containing DNA.
Looking from another perspective, following the comparison of
the aromatic cages, it is conceivable that the natural ligands of
cereblon are methylated lysine or arginine residues in histone tails
or transcription factors. It is established that the DDB1/CUL4 E3
ubiquitin ligase associates with several DCAFs that are core
components of histone methylation complexes (Higa et al., 2006).
Moreover, and more recently, the DCAF ‘‘DCAF1’’ was shown to rec-
ognize monomethylated lysines within a speciﬁc sequence motif,
targeting histone and non-histone proteins for methyl-dependentubiquitination by the DCAF1/DDB1/CUL4 ligase. (Lee et al., 2012).
With an analogous involvement in the recognition of such modiﬁ-
cations, cereblon in its E3 ubiquitin ligase complex could act in a
DNA context, in which the binding of uridine would rather
pose an ancillary effect. However, our binding studies in this direc-
tion were so far inconclusive. It should be noted that also
Chamberlain et al. (2014) (see below) were not able to demon-
strate the binding of small cationic ligands to a thalidomide
binding domain.
The validity and accuracy of the bacterial model system, which
is based on the high sequence similarity and essentially perfect
conservation of the aromatic cage, is further supported by two
recent studies: At the time of submission, Fischer et al. (2014),
and later, during review of this work, Chamberlain et al. (2014)
published crystal structures of cereblon proteins in complex with
IMiD drugs from chicken, human and mouse with the respective
resolutions of 3 Å, 3 Å and 1.9 Å. Fig. 5 shows representative
structures of the thalidomide binding domains from these three
organisms superimposed onto the MsCI4thalidomide complex,
all with RMSD values <1 Å and a virtually identical geometry of
the aromatic cage. Together with our in vivo experiments, verifying
Fig.4. The aromatic cage of the thalidomide binding pocket compared to the aromatic cages for the readout of speciﬁc methylation states of lysines and arginines with the
bound substrates symmetrical dimethylated arginine, asymmetrical dimethylated arginine, trimethylated lysine and dimethylated lysine. PDB codes are given in parenthesis.
For the cages of cereblon and the ankyrin repeat on the bottom right, hydrogen bonds of the tryptophan side chains are indicated.
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eukaryotic cereblon, this further highlights the major advantage
of MsCI4 in allowing for high-resolution binding studies in a
simple and minimal model system.
Using the structural insight gained by the presented crystal
structures, we were able to derive certain structural rules for
cereblon-binding ligands. This is exempliﬁed by the selectivity
for uridine over thymidine and cytosine, showing that the ligand
needs to form speciﬁc hydrogen bonds while conforming to sterical
requirements set by the aromatic cage. As glutarimide and
uracil alone also bind to this pocket, it is conceivable thatFig.5. A comparison of MsCI4thalidomide to IMiD-bound thalidomide binding
domains from human, chicken and mouse, which were published shortly before
submission (chicken) or during peer review (human, mouse) of this work. All
structures superimpose with an RMSD < 1 Å.pharmaceuticals with accessible glutarimide- or uracil-like moie-
ties could have teratogenic effects by binding to cereblon with
the same binding mode. Moreover, it must be considered that
pharmaceuticals might have metabolic products that fulﬁll the
requirements for cereblon binding. In fact, in the performed
in vivo assay, we cannot exclude that at least part of the effect is
due to metabolic products that retained the glutarimide or uracil
moiety. To gain more detailed insight into the speciﬁc structural
parameters for cereblon-mediated teratogenicity, a systematic
study of ligand speciﬁcity in needed. With a more precise knowl-
edge about the structural requirements, pharmaceuticals could
be rationally designed or modiﬁed to speciﬁcally bind - or not to
bind - to cereblon. With this study we provide a robust protein
construct amenable for high-throughput screening and a proof-
of-principle to assess and reﬁne these structural determinants.
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